GLI1 and breast cancer: Therefore, the utility of SMO inhibitors in BC might be limited to subtypes where activation of GLI1 is SMO-dependent, as appears to be the case in TNBC, or during EMT and metastasis, where paracrine activation of the stroma with Hh ligands seems to play an important role.